Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00021697
Status:
COMPLETED
Last Update Posted:
2016-07-14
First Post:
2001-08-01
Brief Title:
SafetyEfficacy of AVP-923 in the Treatment of Emotional Lability Uncontrolled Crying Laughing in Patients With ALS
Sponsor:
Avanir Pharmaceuticals
Organization:
Avanir Pharmaceuticals
Study Overview
Official Title:
A Double-Blind Controlled Multicenter Phase IIIII Study to Assess the Safety and Efficacy of AVP-923 DextromethorphanQuinidine in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare and evaluate the safety of AVP-923 dextromethorphanquinidine for the treatment of emotional lability in ALS patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVP-923 | None | None | None |